Protagonist Therapeutics, Inc. (PTGX) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Newark, CA, アメリカ. 現CEOは Dinesh V. Patel.
PTGX を有する IPO日 2016-08-11, 124 名の正社員, に上場 NASDAQ Global Market, 時価総額 $6.68B.
Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing peptide-based therapeutic drugs for hematology, blood disorders, and inflammatory and immunomodulatory diseases. The company's clinical pipeline includes rusfertide (PTG-300), an injectable hepcidin mimetic in Phase II trials for polycythemia vera and hereditary hemochromatosis; PN-943, an oral integrin antagonist peptide in Phase II development for inflammatory bowel disease; and PN-235, an orally delivered interleukin-23 receptor antagonist for IBD and other indications. Protagonist maintains a license and collaboration agreement with Janssen Biotech, Inc. and operates from its headquarters in Newark, California.
